期刊文献+

仓鼠艰难梭菌相关性腹泻动物模型的建立和评价 被引量:2

Establishment and evaluation of hamster model of Clostridium difficile-associated diarrhea
下载PDF
导出
摘要 目的探索建立仓鼠艰难梭菌相关性腹泻动物模型的方法和评价指标。方法以克林霉素皮下注射为诱导(术前1 d),24 h后以临床分离株KH1(10~6~10~8CFU/mL,核糖体型027)或SH9(10~8~10^(10)CFU/mL,核糖体型001)灌胃。观察不同建模方式下仓鼠的全身情况、腹泻和体重变化。至观察终点(第7天或死亡)行结肠组织病理学检查。结果克林霉素100 mg/kg皮下注射,24 h后分别以艰难梭菌KH1或SH9活菌混悬液灌胃后,KH1 10~8CFU/mL剂量组仓鼠全部出现腹泻,至第5天全部死亡;SH9 10^(10)CFU/mL剂量组亦全部发生腹泻,死亡率为66.7%。其他实验组仅1只仓鼠出现腹泻死亡或无腹泻。腹泻仓鼠有稀便及湿尾现象,体重减轻,结肠黏膜充血水肿伴炎性细胞浸润。结论以100 mg/kg克林霉素皮下注射,24 h后10~8~10^(10)CFU/mL艰难梭菌活菌混悬液灌胃,可建立艰难梭菌相关性腹泻模型。 Objective To explore a method for establishing the hamster model of Clostridium difficile-associated diarrhea(CDAD) and the indicators for its evaluation.Methods Clindamycin was administered to hamsters subcutaneously(day 1).and24 h later infected with C.difficile clinical isolates KH1(ribotype 027,10~6-10~8 CFU/mL) or SH9(ribotype 001,10*-10"'CFU/mL)by gavage.Animals were observed for CDAD symptoms such as diarrhea,weight loss and death.At the end of observation period(day 7 or death),the cecum was collected from each animal for histological evaluation of inflammation.Results Following a single dose of 100 mg/kg clindamycin subcutaneously,all the animals challenged with KH1(10~8 CFU/mL) developed diarrhea and then died within 5 days.All the hamsters challenged with SH9(10~(10) CFU/mL) developed diarrhea as well but only 66.7%died at the end of observation period.Among other groups,only one or none developed diarrhea and then died.The symptoms of hamsters with diarrhea included loose stool,wet tail and weight loss.On histological examination,congestion,hemorrhage and neutrophil infiltration of the mucosa were observed in the hamsters died of CDAD.Conclusions We have successfully established a hamster CDAD model that allows for future investigations.
出处 《中国感染与化疗杂志》 CAS 北大核心 2014年第3期204-209,共6页 Chinese Journal of Infection and Chemotherapy
基金 国家自然科学基金资助项目(81101292,30973594) 上海市浦江人才计划(10PJ1401800)
关键词 艰难梭菌 仓鼠 感染模型 Clostridium difficile hamster infection model
  • 相关文献

参考文献17

  • 1Bauer MP, Notermans DW, Benthem BH, et al. Clostridi- urn difficile infection in Europe:a hospital-based survey[J]. Lancet,2011,377 (9759) :63-73.
  • 2Surawicz CM, Brandt L J, Binion DG, et al. Guidelines for diag- nosis, treatment, and prevention of Clostridium difficile in- fections[J]. Am J Gastroenterol,2013,108(4) :478 498.
  • 3Huang H, Fang H, Weintraub A, et al. Distinct ribotypes and rates of antimicrobial drug resistance in Clostridium dif- ficile from Shanghai and Stockholm[J]. Clin Microbiol In- {eel, 2009,15(12) :1170-1173.
  • 4Chen YB, Gu SL, Wei ZQ, et al. Molecular epidemiology of Clostridium difficile in a tertiary hospital of China[J]. J Med Microbiol, 2013, doi: 10.1099/jmm. 0. 068668-0.
  • 5Sambol SP, Tang JK, Merrigan MM, et al. Infection of ham- sters with epidemiologically important strains of Clostridiurn difficile[J]. J Infect Dis, 200l, 183(12) : 1760-1766.
  • 6Kokkotou E, Moss AC, Michos A, et al. Comparative effiea- eies of rifaximin and vancomycin for treatment of Clostridium difficile-assoeiated diarrhea and prevention of disease recur- rence in hamsters[J]. Antimicrob Agents Chemother, 2008,52(3):1121 1126.
  • 7苏文金,Bourlioux P..对引入仓鼠菌群的C_3H无菌小鼠拮抗艰难梭菌定居实验模型的研究[J].中国微生态学杂志,1990,2(2):24-27. 被引量:4
  • 8王祥,傅思武.非产毒艰难梭菌对艰难梭菌感染BALB/c小鼠的防治作用[J].兰州大学学报(医学版),2009,35(3):35-37. 被引量:3
  • 9Sun X, Wang H, Zhang Y, et al. Mouse relapse model of Clostridium difficile infection[J].Infect Immunol, 2011,79 (7) :2856 2864.
  • 10Pawlowski SW, Calabrese G, Kolling GL, et al. Murine model of Clostridium difficile infection with aged gnotobiot- ic C57BL/6 mice and a BI/NAP1 strain[J]. J Infect Dis, 2010,202( 11 ) : 1708-1712.

二级参考文献12

  • 1BARTLETT J G.Clinical practice,antibioticassociated diarrhea[J].N Engl J Med,2002,346(5):334-339.
  • 2KAMIYA S,TAGUCHI H,YAMAGUCHI H,et al.Bacterioprophylaxis using Clostridium butyricum for lethal caecitis by Clostridium diffcile in gnotobiotic mice[J].Reviews in Medical Microbiology,1997,8(Suppl 1):57-59.
  • 3田口晴彦,神谷茂.無菌マウスを用ぃたClostridium difficile腸炎モデルProbioticsとしてのClostridium butyricumの有用性[J].Progress in Medicine,1997,17:1407-1409.
  • 4CASTEX F,CORTHIER G,JOUVERT S,et al.Prevention of Clostridium difficile-induced experimental pseudomemvranous colitis by Sacch aromyces boulardii:a scanning electron microscopic and microbiological study[J].J Gen Microbiol,1990,136(6):1085-1089.
  • 5YAMAMOTO-OSAKI T,KAMIYA S,SAWAMURA S,et al.Growth inhibition of Clostridium difficile by intestinal flora of infant faces in continuous flow culture[J].J Med Microbiol,1994,40:179-187.
  • 6PEIN J,VALIQUETTE L,COSSETTE B.Mortality attributable to nosocomial Clostridium difficileassociated disease during an epidemic caused by a hypervirulent strain in Quebec[J].Can Med Assoc J,2005,173(9):1037-1042.
  • 7ARCHIBALD L K,BANERJEE S N,JARVIS W R.Secular trends in hospital-acquired Clostridium difficile disease in the United States,1987-2001[J].J Infect Dis,2004,189(9):1 585-1 589.
  • 8SUNENSHINE R H,Me DONALD L C.Clostridium difficile-associated disease:new challenges from an established pathogen[J].Cleve Clin J Med,2006,73(2):187-197.
  • 9TILLOTSON G.Clostridium diffcile-second international symposium (ICDS)[J].I Drugs,2007,10(8):538-542.
  • 10VOTH D E,BALLARD J D.Clostridium difficile toxins:mechanism of action and role in disease[J].Clin microbiol Rev,2005,18(2):247-263.

共引文献5

同被引文献19

  • 1LESSA FC, GOULD CV, MCDONALD LC. Current status of Clostridium difficile infection epidemiology[J]. Clin Infect Dis, 2012, 55 ( Suppl 2 ) : s65-s70.
  • 2RUPNIK M, WILCOX MH, GERDING DN. Clostridium difficile infection : new developments in epidemiology and pathogenesis[J]. Nat Rev Microbiol, 2009, 7 ( 7 ) : 526-536.
  • 3SURAWICZ CM, ALEXANDER J. Treatment of refractory and recurrent Clostridium difficile infection[J]. Nat Rev Gastroenterol Hepatol, 2011, 8 ( 6 ) : 330-339.
  • 4EPSTEIN L, GOLAN Y. Fidaxomiein, a new treatment for Clostridium difficile infections[J]. Drugs Today ( Bare ), 2012, 48 (2) : 101-108.
  • 5HARDESTY JS, JUANG P. Fidaxomicin : a macroeyclic antibiotic for the treatment of Clostridium difficile infection[J]. Pharmacotherapy, 2011, 31 (9) : 877-886.
  • 6LANCASTER JW, MATTHEWS SJ. Fidaxomicin: the newest addition to the armamentarium against Clostridium difficile infections[J]. ClinTher, 2012, 34 ( 1 ) : 1-13.
  • 7MILLER BA, CHEN LF, SEXTON D J, et al. Comparison.of the burdens of hospitalonset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals[J]. Infect Control Hosp Epidemiol, 2011, 32 ( 4 ) : 387-390.
  • 8KUIJPER EJ, VAN DISSEL JT, WILCOX MH. Clostridium difficile: changing epidemiology and new treatment options[J]. Curr Opin Infect Dis, 2007, 20 ( 4 ) : 376-383.
  • 9OKA K, OSAKI T, HANAWA T, et al. Molecular and microbiological characterization of Clostridium diJficile isolates from single, relapse, and reinfection cases[J]. J Clin Microbiol, 2012, 50 (3):915-921.
  • 10CORNELY OA, CROOK DW, ESPOSITO R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA : a double-blind, non- inferiority, randomised controlled trial[J]. Lancet Infect Dis, 2012, 12 (4): 281-289.

引证文献2

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部